Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Developmental Therapeutics in Myeloproliferative Neoplasms.

Bose P, Verstovsek S.

Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S43-S52. doi: 10.1016/j.clml.2017.02.014. Review.

PMID:
28760302
2.

JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Bose P, Verstovsek S.

Blood. 2017 Jul 13;130(2):115-125. doi: 10.1182/blood-2017-04-742288. Epub 2017 May 12. Review.

PMID:
28500170
3.

HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?

Ramos TL, Sánchez-Abarca LI, Redondo A, Hernández-Hernández Á, Almeida AM, Puig N, Rodríguez C, Ortega R, Preciado S, Rico A, Muntión S, Porras JRG, Del Cañizo C, Sánchez-Guijo F.

Oncotarget. 2017 Apr 25;8(17):28187-28202. doi: 10.18632/oncotarget.15969.

4.

Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.

Bose P, Verstovsek S.

Expert Opin Investig Drugs. 2016 Dec;25(12):1393-1403. Epub 2016 Oct 31. Review.

PMID:
27756180
5.

Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway.

Malemud CJ.

Pharmaceuticals (Basel). 2010 May 12;3(5):1446-1455. Review.

6.

Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.

Cramer SD, Aplan PD, Durum SK.

Blood. 2016 Jul 28;128(4):473-8. doi: 10.1182/blood-2016-03-679209. Epub 2016 Jun 6. Review.

7.

Tyrosine 625 plays a key role and cooperates with tyrosine 630 in MPL W515L-induced signaling and myeloproliferative neoplasms.

Yu C, Yang Q, Chen Y, Wang D, Levine R, Crispino J, Wen Q, Huang Z.

Cell Biosci. 2016 May 23;6:34. doi: 10.1186/s13578-016-0097-3. eCollection 2016.

8.

Signal transducer and activator of transcription STAT5 is recruited to c-Myc super-enhancer.

Pinz S, Unser S, Rascle A.

BMC Mol Biol. 2016 Apr 14;17:10. doi: 10.1186/s12867-016-0063-y.

9.

Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms.

Kaplan JB, Stein BL, McMahon B, Giles FJ, Platanias LC.

EBioMedicine. 2016 Jan 13;3:17-25. doi: 10.1016/j.ebiom.2016.01.010. eCollection 2016 Jan. Review.

10.

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.

Mazzacurati L, Lambert QT, Pradhan A, Griner LN, Huszar D, Reuther GW.

Oncotarget. 2015 Nov 24;6(37):40141-57. doi: 10.18632/oncotarget.5653.

11.

Contribution of chaperones to STAT pathway signaling.

Bocchini CE, Kasembeli MM, Roh SH, Tweardy DJ.

JAKSTAT. 2014 Oct 30;3(3):e970459. doi: 10.4161/21623988.2014.970459. eCollection 2014. Review.

12.

Clinical potential of pacritinib in the treatment of myelofibrosis.

Duenas-Perez AB, Mead AJ.

Ther Adv Hematol. 2015 Aug;6(4):186-201. doi: 10.1177/2040620715586527. Review.

13.

Rational Combinations of Targeted Agents in AML.

Bose P, Grant S.

J Clin Med. 2015 Apr 10;4(4):634-64. doi: 10.3390/jcm4040634. eCollection 2015 Apr. Review.

14.

Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function.

Pinz S, Unser S, Buob D, Fischer P, Jobst B, Rascle A.

Nucleic Acids Res. 2015 Apr 20;43(7):3524-45. doi: 10.1093/nar/gkv188. Epub 2015 Mar 13.

15.

Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

Bose P, Dai Y, Grant S.

Pharmacol Ther. 2014 Sep;143(3):323-36. doi: 10.1016/j.pharmthera.2014.04.004. Epub 2014 Apr 24. Review.

16.

The synthetic α-bromo-2',3,4,4'-tetramethoxychalcone (α-Br-TMC) inhibits the JAK/STAT signaling pathway.

Pinz S, Unser S, Brueggemann S, Besl E, Al-Rifai N, Petkes H, Amslinger S, Rascle A.

PLoS One. 2014 Mar 3;9(3):e90275. doi: 10.1371/journal.pone.0090275. eCollection 2014. Erratum in: PLoS One. 2014;9(8):e105845.

17.

Genetics of myeloproliferative neoplasms.

Viny AD, Levine RL.

Cancer J. 2014 Jan-Feb;20(1):61-5. doi: 10.1097/PPO.0000000000000013. Review.

18.

Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.

Bartalucci N, Tozzi L, Bogani C, Martinelli S, Rotunno G, Villeval JL, Vannucchi AM.

J Cell Mol Med. 2013 Nov;17(11):1385-96. doi: 10.1111/jcmm.12162. Epub 2013 Nov 17.

19.

Advances in myelofibrosis: a clinical case approach.

Mascarenhas JO, Orazi A, Bhalla KN, Champlin RE, Harrison C, Hoffman R.

Haematologica. 2013 Oct;98(10):1499-509. doi: 10.3324/haematol.2013.086348. Review.

20.

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.

Gäbler K, Behrmann I, Haan C.

JAKSTAT. 2013 Jul 1;2(3):e25025. doi: 10.4161/jkst.25025. Epub 2013 May 14. Review.

Supplemental Content

Support Center